Symbol | Exchange | Currency |
|---|
By Nell Mackenzie LONDON (Reuters) - In the first half of September bets against sterling posted the biggest two-week rise since 2013, a sign that hedge funds may have ramped up...
By Amanda Perobelli and Pilar Olivares SAO PAULO (Reuters) - A record number of indigenous leaders, most of them women, are running for federal office in Brazil's election next...
By Amanda Perobelli and Pilar Olivares SAO PAULO (Reuters) - A record number of indigenous leaders, most of them women, are running for federal office in Brazil's election next...
Sanctions, terminated contracts, and a plummeting currency – Russia is facing the financial crisis specter. Can gold also be affected? In the medium term, even painfully....
Investors prick up their ears to front-run the Fed’s taper. It looks like a tricky game though, given its contradictory statements. What’s the truth? You Don't Say! At...
Vanda (NASDAQ:VNDA) Pharmaceuticals (VNDA) shares soared 5.8% in the last trading session to close at $21.51. The move was backed by solid volume with far more shares changing...
Vanda Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies to address unmet medical needs. Its commercial portfolio consists of two products, HETLIOZ (tasimelteon) for the treatment of jet lag disorder, pediatric non-24, delayed sleep phase disorder (DSPD) and autism spectrum disorder (ASD), and Fanapt (iloperidone) for the treatment of bipolar disorder and Parkinson's disease psychosis (PDP) and a long acting injectable (LAI) formulation for the treatment of schizophrenia. Its other product pipeline includes Tradipitant (VLY-686), VTR-297, VSJ-110 and BPO-27. VLY-686, is for the treatment of gastroparesis, motion sickness, atopic dermatitis and COVID-19 pneumonia. VTR-297, is for the treatment of hematologic malignancies. VSJ-110, is for the treatment of dry eye and ocular inflammation. BPO-27, is for the treatment of secretory diarrhea disorders, including cholera. Its other product includes VQW-765.
| Average | 10.00 (+4.82% Upside) |
| High | 10 |
| Low | 10 |
| Price | 9.54 |
| No. of Analysts | 1 |
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | Strong Sell | Strong Sell | Strong Sell | Strong Sell | Strong Sell |
| Technical Indicators | Strong Sell | Strong Sell | Strong Sell | Strong Sell | Strong Sell |
| Summary | Strong Sell | Strong Sell | Strong Sell | Strong Sell | Strong Sell |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 115.32 | 117.33 | 113.13 | +1.54 | +1.35% | 50.39M | NASDAQ | |||
| 58.02 | 58.57 | 57.69 | -0.58 | -0.99% | 12.15M | NYSE | |||
| 294.77 | 302.01 | 292.31 | -7.20 | -2.38% | 1.62M | NYSE | |||
| 113.18 | 113.78 | 112.24 | +0.19 | +0.17% | 2.67M | NYSE | |||
| 244.20 | 246.24 | 242.44 | -1.75 | -0.71% | 2.17M | NYSE | |||
| 17.81 | 18.40 | 17.60 | +0.17 | +0.96% | 33.41M | NYSE | |||
| 106.82 | 109.60 | 106.06 | -2.32 | -2.13% | 11.08M | NYSE | |||
| 122.83 | 126.59 | 122.34 | -2.33 | -1.86% | 47.14M | NASDAQ | |||
| 28.34 | 29.94 | 28.33 | -0.43 | -1.48% | 22.65M | NYSE | |||
| 6.54 | 6.84 | 6.44 | -0.19 | -2.90% | 8.54M | NYSE | |||
| 15.73 | 15.98 | 15.58 | -0.28 | -1.75% | 36.53M | NYSE | |||
| 43.91 | 44.33 | 43.67 | -0.17 | -0.40% | 12.57M | NYSE | |||
| 237.78 | 241.45 | 236.90 | -0.14 | -0.06% | 19.05M | NASDAQ | |||
| 11.06 | 11.67 | 10.86 | -0.66 | -5.63% | 735.30K | NYSE | |||
| 66.61 | 68.74 | 66.38 | -1.36 | -1.99% | 71.77M | NASDAQ |